MedTrace Logo

Effects of Augmented Reality (AR) and Transcranial Direct Current Stimulation (tDCS)

NCT07629791 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-07-20

No results posted yet for this study

Summary

The aim of this randomized controlled trial is to determine the effects of Augmented Reality (AR)-based balance training on improving balance and postural control in chronic stroke survivors and whether the addition of transcranial Direct Current Stimulation (tDCS) to AR training produces superior outcomes compared to AR training alone.

Conditions

Interventions

OTHER

Augmented reality combined with tDCS & Convention therapy

Participants will receive 12 sessions over 4 weeks (3 sessions per week), each lasting 60 minutes. Transcranial Direct Current Stimulation (tDCS) will be applied for 15 minutes immediately before the AR balance training session. Each session will consist of 30 minutes of interactive AR-based balance games with real-time visual and auditory feedback, followed by 15 minutes of conventional therapy targeting balance and mobility. All sessions will be supervised by a physiotherapist, and participants' queries during the training will be addressed.

OTHER

Augmented reality combined with Sham & Convention therapy

The participants in this group will undergo 12 sessions over 4 weeks (3 sessions per week), with each session lasting 60 minutes, consisting of 30 minutes of interactive balance tasks through AR-based games with real-time visual and auditory feedback, 15 minutes of conventional physiotherapy-based balance and mobility training, and 15 minutes of sham stimulation using the tDCS setup without active current flow.

Sponsors & Collaborators

  • Riphah International University

    lead OTHER

Principal Investigators

  • Aaleen Fatima, MS-NMPT* · Riphah International Unversity

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-20
Primary Completion
2026-10-20
Completion
2026-11-20

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07629791 on ClinicalTrials.gov